Brookhaven National Laboratory

National Virtual Biotechnology Laboratory Symposium, October 28

Harnessing the unique strengths of DOE to tackle the biotechnology challenges of COVID-19

 

WHAT: A virtual symposium to highlight the impact the U.S. Department of Energy’s (DOE) National Virtual Biotechnology Laboratory (NVBL) has had utilizing the unique capabilities of the DOE to tackle the science and technology challenges associated with COVID-19, and to discuss areas in which the NVBL can have impact in the future. The event is aimed at the S&T community, media, and the general public. All attendees must register (including press, link below).

DATE: Wednesday, October 28, 2020

TIME: 11:30 a.m. –  3:30 p.m. U.S. Eastern Time

WHERE: Zoom virtual symposium. Registration link: https://www.zoomgov.com/webinar/register/WN_1nEkc3YYR2ODU-W0ZzODlA

DETAILS: With perspectives from Chris Fall, Director, Office of Science, DOE, and William A. Bookless, Principal Deputy Administrator of the National Nuclear Security Administration, the event will feature presentations from lead investigators from across the DOE complex who will present progress on:

  • Epidemiological modeling
  • Therapeutics
  • Testing
  • Understanding transport of the virus
  • Solving issues around supply chain challenges

In addition, keynote speakers from outside the NVBL will discuss the upcoming science and technology needs in computing, testing and surveillance, and vaccines.

SPEAKERS

  • NVBL Co-Leads Michelle Buchanan, Oak Ridge National Laboratory, and Stephen Streiffer, Argonne National Laboratory, “Overview of Science & Technology Challenges for COVID”
  • Bruce Tromberg, Director, National Institute of Biomedical Imaging & Bioengineering, National Institutes of Health, “Future S&T Needs: Future of Testing & Surveillance”
  • Jim Brase, Deputy Associate Director for Computation, Lawrence Livermore National Laboratory, “Future S&T Needs: AI/ML and Computing”
  • Greg Burel, President, Hamilton Grace, LLC, “Future S&T Needs: Vaccines”
  • Harriet Kung, Deputy Director for Science, DOE Office of Science, “Closing Remarks”

Full agenda available on the NVBL Symposium website.

The U.S. Department of Energy National Virtual Biotechnology Laboratory (NVBL) is a consortium of DOE national laboratories, each with core capabilities relevant to the threats posed by COVID-19. More information can be found at https://science.osti.gov/nvbl. Funding for NVBL is provided by the Coronavirus CARES Act and distributed by the DOE Office of Science. The Office of Science is the single largest supporter of basic research in the physical sciences in the United States and is working to address some of the most pressing challenges of our time. For more information, visit https://www.energy.gov/science/




Filters close

Showing results

110 of 4179
Released: 2-Dec-2020 7:40 AM EST
No country ‘immune’ to COVID-19 economic shock, but Asian nations will bounce back faster
University of Cambridge

Study uses forty years of quarterly data to project a lengthy global recession from COVID-19 – knocking 3% off world GDP by end of next year. The manufacturing bases of China and East Asia are predicted to fare better than most Western economies.

Released: 1-Dec-2020 7:10 PM EST
American College of Surgeons calls on Congress to prevent CMS Medicare Physician Fee Schedule from taking effect
American College of Surgeons (ACS)

The Medicare Physician Fee Schedule released today by the Centers for Medicare & Medicaid Services (CMS) will harm patients and further destabilize a health care system already under severe strain from the COVID-19 pandemic.

Newswise: UNLV Immunologist on the Differences Between Two Leading COVID-19 Vaccine Candidates
Released: 1-Dec-2020 5:05 PM EST
UNLV Immunologist on the Differences Between Two Leading COVID-19 Vaccine Candidates
University of Nevada, Las Vegas (UNLV)

Millions around the world have waited for news about a COVID-19 vaccine, regarding it as the beginning of the end for the global pandemic and a herald for the eventual return to “normal life.” Recent announcements from pharmaceutical companies Pfizer and Moderna that their respective late-stage vaccine trials have shown a 90% or better effectiveness rate have received international applause, excitement furthered with estimates that doses could be ready as early as December.

Newswise: Why Older Adults Should Shop from Home While the Pandemic is Surging
Released: 1-Dec-2020 4:50 PM EST
Why Older Adults Should Shop from Home While the Pandemic is Surging
Rutgers University-New Brunswick

Leslie M. Kantor, professor and chair of the Department of Urban-Global Public Health at the Rutgers School of Public Health, talks about the new data from Public Health England, the country’s national health service, and explains why even the most independent seniors should avoid grocery shopping at this stage of the pandemic and how to use technology and help from family and friends.

Released: 1-Dec-2020 4:05 PM EST
Primary Care in a Pandemic: Spotting Mental Health Needs and More
Michigan Medicine - University of Michigan

The number of people dealing with mental distress caused by enduring months of pandemic, economic disruption and political turmoil is rising fast. And America’s primary care clinics are the front line for many of those mental health concerns. A new online toolkit aims to help primary care clinics cope with this influx, and draw from the expertise of mental health specialists and researchers.

Released: 1-Dec-2020 3:50 PM EST
New Study Finds Possible Link Between Sight-Threatening Eye Infection and Coronavirus
American Academy of Ophthalmology (AAO)

Researchers are warning of a possible link between a rare and devastating eye infection and COVID-19.

Released: 1-Dec-2020 2:40 PM EST
The claim that COVID-19 vaccines will cause more severe disease through antibody-dependent enhancement is not yet supported
Newswise

ADE has not been shown to occur in individuals that received COVID-19 vaccines to date.

Newswise: Supercomputers Help Model Potential SARS-CoV2 Protease Inhibitors for COVID-19
Released: 1-Dec-2020 1:55 PM EST
Supercomputers Help Model Potential SARS-CoV2 Protease Inhibitors for COVID-19
University of California San Diego

A team of researchers recently created a pharmacophore model and conducted data mining of the database of drugs approved by the U.S. Federal Drug Administration (FDA) to find potential inhibitors of papain-like protease of SARS-CoV2, one of the main viral proteins responsible for COVID-19.


Showing results

110 of 4179

close
0.91121